hapabapa/iStock Editorial via Getty Images The U.S. FDA has approved Bristol-Myers Squibb's ( NYSE: BMY ) CAR-T therapy Breyanzi (lisocabtagene maraleucel) as a third-line treatment for mantle cell lymphoma.
In relapsed or refractory MCL, Breyanzi is given as a one-time infusion. Approval was based on the results of the MCL cohort of the TRANSCEND NHL 001 trial. These patients received at least two prior lines of therapy, including a BTK inhibitor.
Results showed 67.6% of patients achieved a complete response. Breyanzi is also approved for large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.
More on Bristol-Myers Squibb Company Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Bristol-Myers gets EU approval for Opdivo for bladder cancer Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo.
